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Abstract: Gadofosveset (Vasovist®, Bayer Schering Pharma AG, Berlin/Germany) is the 
ﬁ  rst intravascular contrast agent approved for use with magnetic resonance angiography in the 
European Union, Switzerland, Turkey, Canada, and Australia. Gadofosveset reversibly binds 
to albumin providing extended intravascular enhancement compared wth existing extracellular 
magnetic resonance contrast agents. Prior to approval, gadofosveset underwent extensive testing 
to evaluate the safety and efﬁ  cacy of the drug; the clinical trials show that gadofosveset-enhanced 
magnetic resonance angiography (MRA) is safe and well tolerated in patients with vascular 
disease and effective for the detection of vascular stenosis and aneurysms gadofosveset has the 
potential to open new horizons in diagnostic MRA by increasing the spatial resolution and the 
robustness of MRA examinations and facilitating the examination of multiple vascular beds.
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agent, magnetic resonance angiography (MRA)
Introduction
Atherosclerosis is a generalized disease and contributes to cardiac death, stroke, limb 
loss, and a range of other illnesses. Disease in the major arteries, including the infra-
renal abdominal aorta, internal iliac arteries, renal arteries, and peripheral vasculature 
remains a major cause of morbidity and mortality. For example, the prevalence of 
disease in the infra-renal abdominal aorta ranges from  3% in patients  60 years old 
to 20% in patients  75 years (Criqui et al 1985; Vogt et al 1992), and the incidence 
increases with increasing age. As the average age of the population increases, the 
burden of vascular disease is expected to increase.
Until recently, conventional X-ray angiography (XRA) requiring arterial catheteri-
zation and the use of substantial volumes of iodinated contrast agent was the clinical 
standard practice when a detailed image of the vasculature was required; however, 
less invasive imaging techniques using X-ray computed tomography (CT) or mag-
netic resonance imaging (MRI) have been developed. These imaging methods, either 
without exogenous contrast agents (MRI only) or with exogenous contrast agents 
(both CT and MRI) have become increasingly popular over the past few years as data 
have suggested that their accuracy, in some clinical settings, might approach that of 
the accepted standard diagnostic method, catheter X-ray angiography (XRA) using 
iodinated contrast agents (Rieker et al 1997; Grist 2000; Tan et al 2002).
MRI is a safe, non-invasive, and widely available imaging technique that has 
experienced rapid growth over the past decade. Magnetic resonance angiography 
(MRA), as a more recent development in MRI, uses tailored acquisition sequences 
to highlight blood ﬂ  ow and is widely used to assist in the management of patients 
with vascular diseases, especially in the brain. In many vascular beds like peripheral 
vessels, however, non-contrast MRA is not used routinely in clinical practice due to 
shortcomings of unenhanced MRA.Vascular Health and Risk Management 2008:4(1) 2
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What is gadofosveset?
Gadofosveset is the ﬁ  rst intravascular contrast agent approved 
for use with MRA in the European Union, Switzerland, Turkey, 
Canada, and Australia. Gadofosveset reversibly binds to human 
serum albumin, providing signiﬁ  cantly higher relaxivity and 
extended intravascular enhancement compared to existing extra-
cellular magnetic resonance contrast agents (Table 1).
MS-325 is the product development code for the drug 
product containing trisodium-{(2- (R)-(4,4-diphenylcycloh
exyl)phosphonooxymethyl)-diethylenetriaminepentaacetato) 
(aquo) gadolinium(III)} (INN (international non-proprietary 
name) = gadofosveset trisodium) as the active substance. 
Gadofosveset is commercially available as Vasovist® (Bayer 
Schering Pharma AG, Berlin/Germany). Gadofosveset 
injection is composed of an aqueous solution (244 mg/mL, 
0.25 mmol/L) of drug substance, gadofosveset trisodium, and 
a small amount of ligand excipient, fosveset, to ensure mini-
mal free gadolinium in solution. The drug substance consists 
of a stable gadolinium diethylenetriaminepentaacetic acid 
(Gd-DTPA) chelate substituted with a diphenylcyclohexyl-
phosphate group. Gadofosveset injection is a clear, colorless 
to slightly yellow solution in which the pH has been adjusted 
to 6.5 to 8.0. The density is 1.12 g/mL and the osmolality 
ranges from 700 to 950 mOsm/kg at 37 °C. The viscosity of 
MS-325 injection ranges from 2.7 to 3.3 cps at 20 °C. The 
molecular formula is C33H40GdN3Na3O15P and the molecular 
weight for the anhydrous form is 975.88. Gadofosveset is 
administered either by a hand or power injector to deliver a 
dose of 0.03 mmol/kg (in 7–20 seconds).
Overview of the clinical development 
program
Prior to approval in the European Union, gadofosveset 
underwent extensive evaluation of the safety and efﬁ  cacy 
of the drug. The clinical development program for efﬁ  cacy 
included two phase II studies and four phase III studies. In 
phase II studies, approximately 300 patients were evaluated 
to deﬁ  ne optimal dose for MRA. The optimal dose for MRA 
was found to be 0.03 mmol/kg.
The clinical effectiveness of gadofosveset was demon-
strated through analysis of efﬁ  cacy data of 672 patients that 
were included in four adequate and well-controlled phase III 
studies. Vascular beds representative of areas of turbulent 
blood ﬂ  ow (AIOD: aorto-iliac occlusive disease), ﬂ  ow to an 
organ (renal artery disease), and slow ﬂ  ow (pedal arterial 
disease) were studied. In all of these studies, the fundamental 
methodology was the same:
•  Each study was designed to evaluate and quantify the 
improvement provided by the administration of gadofos-
veset compared with the MRA device alone (TOF-MRA) 
using XRA as the standard of reference (SOR);
•  All images were acquired using prospectively deﬁ  ned 
imaging protocols;
•  The efﬁ  cacy evaluation of all studies included blinded 
reading and 3 independent blinded readers for each study 
were used. These blinded readers had no prior afﬁ  liation 
with the sponsor, and had not participated in other gado-
fosveset studies;
•  A total of 32 independent blinded readers (24 radiolo-
gists, 8 vascular surgeons) were used in the four studies. 
Vascular surgeons were asked to evaluate the images for 
management decisions;
•  Images were randomized and no other clinical informa-
tion was provided to the blinded readers;
•  Three different blinded readers evaluated XRA images to 
develop the SOR (2 readers plus 1 adjudicator). No con-
sensus reading was performed in determining the SOR.
Summary of efﬁ  cacy results of four phase 
III studies
Gadofosveset reduced the rate of uninterpretability signiﬁ  -
cantly and improved the diagnostic conﬁ  dence (Goyen et al 
2005; Rapp et al 2005). Fewer than 2.3% were uninterpret-
able for gadofosveset-enhanced MRA, versus approximately 
16% for 2D-TOF. For comparison, 2.8% of the vessels were 
deemed uninterpretable on XRA. For all readers in all studies, 
the vascular surgeon readers agreed with XRA more often 
when using gadofosveset-enhanced MRA than when using 
pre-contrast MRA (range of improvements: 1%–36%). For 
six of the eight readers, the improvement was substantial 
( 15%) and statistically signiﬁ  cant (p   0.001).
Safety data for gadofosveset
Safety data in 767 patients (505 males and 262 females) 
receiving 0.03 mmol/kg bw dose have been reported. There 
were no clinically signiﬁ  cant trends found in adverse events, 
laboratory assays, vital signs, ECGs, or oxygen saturation. 
Table 1 Relaxivity (r1) in human plasma at 37 ºC (mM-1s-1)
 Field  strength
 0.47T  1.5T  3.0T
Gd-DTPA 3.8  4.1  3.7
Vasovist® 28–47  19–28  10–19
Relative increase  8–12x  5–7x  3–5xVascular Health and Risk Management 2008:4(1) 3
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Gadofosveset has a good safety proﬁ  le and can be safely 
administered as an intravenous bolus injection. The overall 
rate and experience of adverse events was comparable to 
placebo and were similar to that reported in clinical trials 
for other Gd chelates.
Clinical applications 
of gadofosveset-enhanced MRA
Considering the enormous success of extracellular gadolin-
ium-based contrast agents for contrast-enhanced MRA, what 
is likely to be the role for an intravascular contrast agent such 
as gadofosveset? The answer lies in the key question: can 
gadofosveset be used in ﬁ  rst-pass (arterial) imaging with equal 
effect? As the answer appears to be yes, this suggests that 
gadofosveset can be used instead of the current extracellular 
contrast agents for ﬁ  rst-pass arterial imaging (Klessen et al 
2007) (Figures 1–4). The crucial advantage of gadofosveset, 
ie, the presence of persistent high intravascular enhancement 
signiﬁ  cantly greater than with extracellular agents, can be 
exploited to acquire additional high-resolution images in 
Figure 1 Gadofosveset-enhanced MRA data of a 30-year old healthy proband: after contrast agent injection and by using new multi-channel MR scanners, a MRA in dynamic 
or ﬁ  rst-pass phase with purely arterial contrast can be realized for both the carotid arteries and the lower thigh arteries (A, spatial resolution: 1.0 mm³ voxel size, subtracted 
maximum-intensity projections (MIP), acquisition time: 29 seconds). In the following acquisition performed during the equilibrium phase, very high spatial resolutions of below 
0.1 mm³ voxel size can be achieved, which, at a satisfactory signal-to-noise ratio, permit sufﬁ  cient differentiation between arterial and venous vascular structures despite the 
small vascular diameter and the close proximity of the structures (B, C (enlarged view), 0.074 mm³ voxel size, acquisition time: 6:15 minutes, arrows: veins; arrow heads: 
arteries). Image: courtesy Konstantin Nikolaou, reproduced from Mathias Goyen (ed.). 2006. Vasovist – the ﬁ  rst intravascular contrast agent for MR angiography.   ABW-
Wissenschaftsverlag Berlin.Vascular Health and Risk Management 2008:4(1) 4
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the steady-state which lead to a better delineation of vessel 
pathology. Steady-state imaging offers the possibility of 
depicting the entire vascular system without relevant extrava-
sation of the contrast medium from the intravascular space. 
The extended diagnostic window of gadofosveset makes the 
examination more convenient because it is less dependent 
on the bolus dynamics.
General considerations
Gadofosveset can be used in exactly the same way as extra-
cellular agents with regard to ﬁ  rst-pass imaging. The advan-
tage of using gadofosveset for ﬁ  rst-pass imaging lies in its 
much higher relaxivity (Rohrer et al 2005). This means that a 
higher signal-to-noise ratio can be obtained when parameters 
are kept identical or, conversely, that spatial resolution can be 
increased while maintaining the same signal-to-noise ratio. 
The truly interesting property of gadofosveset, however, is 
its much longer intravascular residence time. Equilibrium 
imaging is possible because, despite the fact that dilution of 
the injected contrast medium after ﬁ  rst arterial passage leads 
to a T1 increase of the blood pool compared with the ﬁ  rst 
pass, the value is still much lower than that of fat. Hartmann 
et al (2006) estimated that T1 of blood in the equilibrium 
phase, 3–5 minutes after injection of 0.03 mmol/kg gadofos-
veset, is about 130 ms, increasing to about 150 ms after 10–15 
minutes. This prolonged T1 reduction offers the opportunity 
to obtain images of the vascular tree up to about 45–60 min-
utes after injection. The extended imaging window can be 
used to acquire images with much higher spatial resolution 
without a signiﬁ  cant loss of vessel-to-background contrast 
(Figure 1). In clinical practice this means that scan duration 
is no longer determined by the transient T1 shortening, but 
by the capacity of the patient to sustain a breath-hold or to 
remain motionless. A possible drawback of using gadofos-
veset is the simultaneous enhancement of venous structures 
close to arteries. This phenomenon is a well-known problem 
Figure 2 Example of a healthy proband whole-body MRA: compilation of a gadofosveset-enhanced whole-body MRA with acquisition of the carotid arteries (A) and the lower 
thigh arteries (B) in the dynamic and ﬁ  rst-pass phase (for acquisition parameter refer to Table 1), as well as acquisition of the thoracic area (C, voxel size 1.0 mm³, acquisition 
time: 37 seconds), abdomen (D, voxel size 1.0 mm³, acquisition time: 35 seconds). The signal-to-noise ratio that can be achieved in the equilibrium phase is even sufﬁ  cient for 
satisfactory imaging of the coronary arteries (E, voxel size: 0.7 mm³, navigator technology, acquisition time: 3:30 min). Ao: aorta; arrow: right coronary artery. Image courtesy 
Konstantin Nikolaou, reproduced from Mathias Goyen (ed.). 2006. Vasovist – the ﬁ  rst intravascular contrast agent for MR angiography, ABW-Wissenschaftsverlag Berlin.Vascular Health and Risk Management 2008:4(1) 5
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at ﬁ  rst-pass imaging, often resulting in images that cannot be 
used for clinical decision-making. However, because equi-
librium phase images can be acquired at much higher spatial 
resolution – often with a 5–15-fold decrease in voxel size 
compared with ﬁ  rst-pass protocols – arteries can be readily 
separated from accompanying veins.
Practical aspects
The use of gadofosveset has reduced the deleterious conse-
quences of missing the bolus in the ﬁ  rst pass. If, for whatever 
reason, acquisition in the ﬁ  rst pass fails, images can always 
be obtained in the equilibrium phase because of the prolonged 
intravascular retention. Although prolonged intravascular 
retention is highly advantageous, it is not recommended to 
perform a test bolus when using gadofosveset because of this 
property. If possible, it is better to acquire a dynamic series 
of acquisitions using a time-resolved MRA technique and to 
evaluate the data set with the best selective arterial opaciﬁ  ca-
tion. The most commonly used format to display 3-D MRA 
data is the maximum intensity projection (MIP). Although 
MIP is an elegant way to collapse a 3-D volumetric data 
set into a 2-D projection, review of cross-sectional images 
remains an integral part of the evaluation, especially for data 
acquired in the equilibrium phase. The MIP algorithm works 
A B
Figure 3 Sixty-four-year-old male presented with known peripheral vascular disease. The MRA suggests an occlusion of the ﬁ  bular artery at the level of the distal calf on the 
ﬁ  rst-pass image: the vessel cannot be identiﬁ  ed even on the curved MPR (A) due to venous overlay (A). However, curved MPR of the higher spatial resolution steady-state 
images (B allows for clear identiﬁ  cation of the distal ﬁ  bular artery next to the ﬁ  bular vein and allows for depiction of the distal collateral ﬁ  lling of the posterior tibial artery. 
Image courtesy Winfried Willinek, Department of Radiology, University of Bonn/Germany).Vascular Health and Risk Management 2008:4(1) 6
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best when using thin-slab or curved subvolume selections. 
In whole-volume MIPs, contrast-enhancing organs or other 
vascular structures may superimpose over smaller arteries 
when they have higher signal intensities along a particular 
viewing path. When working with equilibrium-phase images, 
the use of thin-slab sub-volume MIPs can be particularly use-
ful. Another helpful technique for the precise evaluation of 
vessel morphology, especially when evaluating equilibrium 
phase data, is curved multiplanar reformation (cMPR) 
along the axis of the arterial segment of interest. Most 
post-processing workstations offer the ability to interactively 
generate a cMPR while scrolling through source images. This 
technique is particularly useful to obtain views of eccentric 
stenoses, and as a basis to generate views perpendicular to 
the central axis of the vessel to measure cross-sectional area 
reduction in stenoses.
Gadofosveset-enhanced MRA 
of the abdomen
For the diagnostic assessment of the abdominal vasculature, 
contrast-enhanced (CE)-MRA – together with computed 
tomography angiography (CTA) – has become the clinically 
accepted standard of reference and has replaced conventional 
digital subtraction angiography. In abdominal aortic aneurysm 
or dissection, CE-MRA allows a simultaneous assessment 
of the aneurysmal extent and involvement of the renal, vis-
ceral or iliac arteries. With gadofosveset, the ﬁ  rst pass of the 
compound can be used for time-resolved MRA, allowing a 
dynamic assessment of the perfusion of the visceral organs and 
visualization of blood-ﬂ  ow differences in the true and false 
lumen of aortic dissection (Schoenberg et al 1999). In patients 
with endovascular repair of abdominal aortic aneurysm, 
blood-pool agent-enhanced MRA might be more accurate 
for the detection of endoleakage than contrast-enhanced CT 
(Ersoy et al 2004). In patients with atherosclerotic disease, the 
potential to increase the spatial resolution during the steady 
state promises a higher accuracy for the detection of vascular 
stenoses than conventional MRA with extracellular contrast 
agents. In patients with aortoiliac disease, Vogt et al (2007) 
reported a higher agreement regarding stenosis location and 
degree of stenosis of gadofosveset-enhanced MRA and DSA 
compared with a non-contrast, time-of-ﬂ  ight MRA.
In a study by Nikolaou et al (2006), gadofosveset-
enhanced MRA showed a sensitivity of 97%–100% and 
speciﬁ  city of 96%–100% for the assessment of high-grade 
stenosis in different vascular territories (eg, carotid or renal 
arteries) compared with the clinical standard of reference. 
In this study the intermodality agreement between the 
gadofosveset-enhanced imaging and reference CE-standard 
imaging data was 90%–93%.
CE-MRA is the clinical gold standard for the detection of 
renal artery stenosis (RAS). Due to the limited breath-hold 
capacity of the patients, imaging has to take place during 
suspended breath-hold, limiting acquisition time and thereby 
reducing the spatial resolution. While proximal RAS can still 
be safely detected, ﬁ  bromuscular dysplasia (FMD) may poten-
tially evade detection. Gadofosveset as a blood pool contrast 
agent may overcome this limitation of MRA by facilitating 
longer respiratory-gated MRA acquisitions. Due to the wide-
spread use of 3-D post-processing tools, the venous signal does 
not interfere with diagnostic image reading. In addition, the 
ﬁ  rst pass of the contrast agent can be used to measure renal 
perfusion (Michaely et al 2006). Due to the high relaxivity 
A
Figure 4AVascular Health and Risk Management 2008:4(1) 7
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of gadofosveset, only a fraction of the amount of gadolinium that 
would be required for extracellular contrast agents is needed. 
This is of particular interest in view of the recently described 
disease ‘nephrogenic systemic ﬁ  brosis’, which is more likely 
to occur when higher doses of gadolinium are administered 
(Leiner et al 2007). Gadofosveset may also be valuable in 
patients who are being evaluated as potential renal donors, as
 the entire abdomino-pelvic arterial and venous system can be 
examined after a single injection of contrast agent. This eases 
workﬂ  ow and should eventually be more cost-efﬁ  cient.
Gadofosveset-enhanced MRA 
of the thorax
The assessment of the pulmonary arteries for pulmonary 
embolism is an interesting application for gadofosveset-
enhanced MRA. Although CT is nowadays the ﬁ  rst-line 
imaging tool for the assessment of patients with suspected 
pulmonary embolism, contrast-enhanced MRI is very 
appealing as it allows for a comprehensive radiation-free 
assessment of pulmonary perfusion and direct visualization 
of embolic material in the pulmonary arteries using a single 
contrast agent injection. Moreover, MR venography of the 
deep venous system can be added for the assessment of 
underlying deep venous thrombosis without an additional 
contrast agent (Fink et al 2004). Recently, an animal study 
indicated that the higher relaxivity of a blood pool contrast 
agent together with the increased signal-to-noise ratio of 3 T 
effectively supports highly accelerated, parallel acquisition, 
time-resolved pulmonary MRA (Nael et al 2007).
For cardiac imaging, the direct visualization of coronary 
arteries is a major challenge for MRI. Although multislice-
CT coronary angiography is now the preferred non-invasive 
imaging technique for the assessment of coronary disease, 
blood-pool contrast agents may change the role of CE-MRA. 
Animal and volunteer studies of coronary MRA using blood-
pool agents have been reported by different authors using 
different blood-pool contrast agents. Though heterogeneous 
in their set-up, all studies reported a signiﬁ  cant advantage 
B
Figure 4 Patient with symptomatic abdominal aortic aneurysm referred for peripheral MRA. The high grade stenosis of the left internal carotid artery was conﬁ  rmed by 64 
multi-slice CTA and the patient was discharged after successful thrombendarterectomy and aneurysm repair. After ﬁ  rst-pass MRA of the abdomen and lower extremities 
(A), an ultra-sonographically suspected stenosis of the left internal carotid artery is conﬁ  rmed by the 0.66 mm isotropic resolution steady-state gadofosveset-enhanced MRA 
(B, arrow). This approach facilitates the pre-operative work-up of patients with systemic vascular disease without the need of a second contrast injection or a separate MR-
examination. Image courtesy Winfried Willinek, Department of Radiology, University of Bonn/Germany.Vascular Health and Risk Management 2008:4(1) 8
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in coronary imaging compared with extracellular contrast 
agents (Shoenberg et al 1999; Li et al 2001; Huber et al 2003; 
Sakuma et al 2005; Zheng et al 2005). A ﬁ  nal assessment of 
the clinical value of this method is still pending.
Gadofosveset-enhanced MRA 
of the peripheral vasculature/
whole-body MRA
CE-MRA of the peripheral vasculature has evolved over the 
past few years from an experimental imaging modality to 
a technique that is now widely applied in clinical practice. 
The recent introduction of gadofosveset expands the diag-
nostic armamentarium of the radiologist by opening up new 
opportunities in the ﬁ  eld of peripheral MRA. The higher 
relaxivity and prolonged intravascular residence time of 
gadofosveset yield better ﬁ  rst-pass image quality, as well as 
the possibility of obtaining additional steady-state MRA data. 
The latter property will lead to a fundamental paradigm shift in 
MR imaging of the vasculature, enabling the migration to equi-
librium-phase ultra-high spatial resolution imaging sequences. 
Initially, there were concerns in regard to the presence of 
venous overlay on the steady-state 3D-CE-MRA data sets, 
particularly for arteries with small vessel calibre and close-
by coursing veins such as in the distal calves. However, with 
today’s optimized surface coils and the use of PAT, isotropic 
voxel sizes of less than 100 µm3 can now be acquired in reason-
able scan time of approximately 5 min (Nikolaou et al 2006) 
(Figure 1, Figure 3). Due to the absence of motion artefacts in 
the peripheral arteries, exquisite image quality can be achieved 
allowing already for visual artery-vein separation despite the 
close proximity of theses vessels. Artery-vein separation can 
be further enhanced by the use of semi-automated software, 
which is currently under preparation by different vendors. 
Gadofosveset-enhanced MR imaging of the venous system 
is ideally suited to the detection of venous thromboembolic 
disease. Deep venous thrombi, even below the knee, are 
readily detected (Li et al 2007) Furthermore, in patients with 
massive thromboembolic occlusion of central veins, the col-
lateral pathways can reliably be visualized in a fashion that is 
superior to conventional X-ray-based venography.
With the introduction of whole-body MRI scanners with 
multiple independent rf-channels and inbuilt coil systems for 
large anatomic coverage this approach becomes attractive 
for assessment of the entire vasculature by a combination 
of multi-station ﬁ  rst-pass 3D-CE-MRA and steady-state 
3D-CE-MRA. This shifts the focus of MRA away from 
solely displaying vascular anatomy to a more disease spe-
ciﬁ  c imaging approach. One example includes the systemic 
assessment of atherosclerotic disease, which has been 
shown as an arising application for screening of cardiovas-
cular risk factors in preliminary studies (Kramer et al 2005) 
(Figures 2–4). This systemic angiographic assessment is also 
of high interest for patients with vasculitis such as Takayasu 
arteriitis that manifests in multiple different locations. Here, 
the combination of ﬁ  rst-pass 3D-CE-MRA of the carotid and 
renal arteries in combination with high-resolution assess-
ment of the inﬂ  ammatory stenoses could improve the overall 
diagnostic work-up of the patients and replace a more time-
intensive, multi-step, multi-modality approach.
Conclusion
Gadofosveset-enhanced MRA is safe and well tolerated in 
patients with vascular disease, effective for the detection of 
vascular stenosis and aneurysms, signiﬁ  cantly more accurate 
(both more sensitive and speciﬁ  c) than non-contrast MRA 
for the diagnosis of vascular stenoses, and similar to conven-
tional angiography for the overall characterization of vascular 
disease, without the need for catheterization. Gadofosveset 
has the potential to open new horizons in diagnostic MRA by 
increasing the spatial resolution and the robustness of MRA 
examinations and facilitating the examination of multiple 
vascular beds.
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